A Phase 4 interventional study of Placebo and Risperidone high dose in Autistic Disorder and Autism, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. Completed at 20 sites in United States. Open to participants aged 5 Years to 17 Years. Per ClinicalTrials.gov, last updated 2014-05-09.
Sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (part of Johnson & Johnson) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 603 studies in Autistic Disorder with a site in United States — 123 open to participants now, 152 under way, 3 of them phase 3. Autistic Disorder · United States.
Among the 603 studies in Autistic Disorder with a site in United States, this one is the 134th largest by enrollment of the 504 interventional ones that give a count, is one of 18 that started in 2007, is one of 18 in phase 4, and was the 78th registered.
1,033 studies on the registry are indexed under Autistic Disorder; 269 are open to participants now.
Browse Autistic Disorder studies →123 of the 603 studies in Autistic Disorder with a site in United States are open now. Recruiting first, the newest first:
Children's Mercy Hospital Kansas City · Sites in United States
Ages 8–12
Vanderbilt University Medical Center · Sites in United States
Ages 36 mo–72 mo
University of Wisconsin, Madison · Sites in United States
Massachusetts General Hospital · Sites in United States
Ages 7–17
Stony Brook University · Sites in United States
Ages 12–17
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 183 Autistic Disorder studies recruiting now, 33 (18%) set no upper age limit and 143 (78%) stop at 75 or younger; 148 take children under 18; 56 take healthy volunteers.
This study: 5 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
603 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 55 · Phase 2 122 · Phase 3 43 · Phase 4 18
First in 1997; this study’s year is marked. 18 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 96 is above the median of 49 across 813 interventional studies indexed under Autistic Disorder.
Median enrollment 44 across the 504 interventional studies, 135 across the 96 observational. Of the 408 that completed or were terminated, 143 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
73 of 603 have an industry lead sponsor. The 10 most frequent:
This study is registered under Johnson & Johnson Pharmaceutical Research & Development, L.L.C., one of the names counted as Johnson & Johnson. Under that name alone:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. is the lead sponsor of 465 studies on the registry; none are open to participants now.
Johnson & Johnson has 4 studies filed under Autistic Disorder — fewer than ten, so there is no comparison to draw.
34 of the studies in Autistic Disorder with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02914951Yale UniversityCognitive-Behavioral Therapy for Irritability in Children With Autism Spectrum Disorder and Intellectual Disability | 2026-12 |
| NCT06627205Stanford UniversitySleep Restriction Therapy (SRT) for Sleep Problems in Children With Autism | 2026-12 |
| NCT04805957Rutgers, The State University of New JerseyValidation Digital Bio-markers During Sulforaphane Treatment. | 2026-12-01 |
| NCT07421830Northeastern UniversityAn Empowering Parent Training Intervention to Increase Physical Activity in Preschool Aged Children With Autism | 2026-12-31 |
| NCT02000284University of ArkansasMitochondrial Dysfunction in Autism Spectrum Disorder | 2026-12-31 |
Add all 34 to your calendar (.ics) → With an account.
Among the 603 studies in Autistic Disorder with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the effectiveness (change in level of irritability and related behaviors) and safety and tolerability of the administration of 2 different fixed dose levels of risperidone (an atypical antipsychotic drug) compared with placebo in children or adolescents who have autism, and to evaluate the safety and tolerability of the drug for additional 26 weeks after the initial 6-week study period.
Autistic Disorder is a condition that develops early in childhood and persists throughout life. Seventy-five percent of children and adolescents with autistic disorder have irritability symptoms such as aggression towards others, deliberate self-injurious behavior, temper tantrums, and quickly changing moods. These symptoms affect their daily functioning such as school performance, interactions with family members and compliance to treatment. Risperidone is an atypical antipsychotic agent that has been recently approved for the treatment of irritability associated with Autistic Disorder in children and adolescents aged 5 to 16 years. The approved dose range is 0.5-3 mg per day. The aim of this study is to evaluate the effectiveness (change in level of irritability and related behaviors) of a lower dose (0.125 mg or 0.175 mg risperidone per day depending on body weight). The study will include three treatment groups. A placebo group, a low dose risperidone group and a higher dose risperidone group (1.25 mg or 1.75mg per day depending on body weight). This phase of the study will be 6 weeks. During the study, neither investigators nor the patients will be told which treatment the patient received. This is called "double blind". The placebo treatment is not expected to be effective. The higher dose group is expected to be effective. At the end of the study, data from the lower dose group will be compared to the placebo group to see if it is effective. Another aim of this study is to evaluate the safety and tolerability of risperidone. At the end of the 6-week double-blind period, patients may enter a 6-month open-label period during which all patients will receive risperidone. During this phase of the study, the doses can be adjusted to a maximum of 1.25 mg or 1.75mg per day depending on body weight. Both investigator and the patient will know what dose the patient is taking. About 93 patients will be randomized. The study will be conducted by investigators from about 15 clinics. Assessments of effectiveness include the Aberrant Behavior Checklist (ABC) subscales including the irritability subscale (ABC-I), the Clinical Global Impression of Change (CGI C); the Clinical Global Impression of Severity (CGI-S); the response rate, and the Compulsions Subscale of the Children's Yale-Brown Obsessive Compulsive Scale (CY BOCS). Safety evaluations include monitoring of adverse events, physical examinations, clinical laboratory tests, nighttime sleep quality and daytime drowsiness, and extrapyramidal symptoms (EPS) as assessed using the Abnormal Involuntary Movement Scale (AIMS), the Barnes Akathisia Rating Scale (BARS) and the Simpson-Angus Scale (SAS). Venous blood samples will be collected for the determination of plasma concentrations of risperidone and 9-hydroxyrisperidone. The study hypotheses are that the higher dose level of risperidone is significantly superior to placebo as measured by change from baseline on the ABC-I Subscale score at end point (Week 6 or early withdrawal) and that the lower dose level of risperidone is significantly superior to placebo as measured by change from baseline on the ABC-I Subscale score at end point (Week 6 or early withdrawal). Double-blind phase: Risperidone oral solutions taken once daily. Depending on body weight patients take 1.25 mL or 1.75 mL of either a 0.1 mg/mL or a 1.0 mg/mL risperidone solution or matching placebo, for 6 weeks. Open-label phase: Medication can be taken once or twice a day. Starting from 0.125mg or 0.175mg per day, drug levels are titrated over 2 weeks to a maximum dose level of 1.25 mg risperidone/day or 1.75 mg /day depending on body weight, for 26 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Risperidone low dose Risperidone oral solution 0.125 mg (if \<45 kg) or 0.175 mg (if \>=45 kg) qd or bid for 6 weeks
Drug: Risperidone low dose
Risperidone high dose Risperidone oral solution 1.25 mg (if \<45 kg) or 1.75 mg (if \>=45 kg) qd or bid for 6 weeks
Drug: Risperidone high dose
Placebo Oral solution qd or bid for 6 weeks
Drug: Placebo
Oral solution qd or bid for 6 weeks
Risperidone oral solution 1.25 mg (if \<45 kg) or 1.75 mg (if \>=45 kg) qd or bid for 6 weeks
Risperidone oral solution 0.125 mg (if \<45 kg) or 0.175 mg (if \>=45 kg) qd or bid for 6 weeks
Change in Aberrant Behavior Checklist Irritability (ABC-I) Subscale
Measure of irritability symptoms of autism. Score range 0 to 45 (lower score = lesser severity).
Time frame: Baseline and 6 weeks
Number of Participants Who Had at Least 25% Improvement in ABC-I
ABC-I is a measure of irritability symptoms of autism with score range 0 to 45 (lower score = lesser severity).
Time frame: 6 weeks
Change in Clinical Global Impression Severity (CGI-S)
Investigator evaluation of severity of illness and functional impairment on a 7-point scale (1="not ill", 2="very mild", 3="mild", 4="moderate", 5="marked", 6="severe", 7="extremely severe").
Time frame: Baseline and 6 weeks
Number of Participants Who Had Clinical Global Impression Change Ratings of Much or Very Much Improved.
Investigator impression of change over time from double-blind baseline on a 7-point scale (1="very much improved", 2="much improved", 3="minimally improved", 4="no change", 5="minimally worse", 6="much worse", 7="very much worse").
Time frame: 6 weeks
Change in Fasting Glucose (mg/dL) at 6 Weeks
Time frame: Baseline and 6 weeks
Change in Insulin Resistance (IR) at 6 Weeks
Insulin resistance calculated using the homeostatic model assessment 1 (HOMA1)formula: fasting glucose (mmol/L) times fasting insulin (uU/L) divided by 22.5. HOMA-IR is a widely used clinical tool for estimating insulin resistance based upon the balance between glucose output and insulin secretion. Normal values should be close to 1, while an increase indicates a decrease in insulin sensitivity (or increase in insulin resistance), a potential predictor for the development of Type 2 Diabetes Mellitus.
Time frame: Baseline and 6 weeks
Change in Fasting Glucose (mg/dL) at 6 Months
Time frame: Baseline and 6 months
Change in Insulin Resistance (IR) at 6 Months
Insulin resistance calculated using the homeostatic model assessment 1 (HOMA1) formula: fasting glucose (mmol/L) times fasting insulin (uU/L) divided by 22.5. HOMA-IR is a widely used clinical tool for estimating insulin resistance based upon the balance between glucose output and insulin secretion. Normal values should be close to 1, while an increase indicates a decrease in insulin sensitivity (or increase in insulin resistance), a potential predictor for the development of Type 2 Diabetes Mellitus.
Time frame: Baseline and 6 months
| Milestone | Placebo | Risperidone Low Dose | Risperidone High Dose | Placebo/RIS | Ris Low Dose/RIS | Ris High Dose/RIS |
|---|---|---|---|---|---|---|
| Started | 35 | 30 | 31 | 0 | 0 | 0 |
| Completed | 27 | 25 | 25 | 0 | 0 | 0 |
| Not completed | 8 | 5 | 6 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 1 | 3 | 0 | 0 | 0 |
| Withdrew: Other | 0 | 2 | 1 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 6 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 1 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Placebo | Risperidone Low Dose | Risperidone High Dose | Placebo/RIS | Ris Low Dose/RIS | Ris High Dose/RIS |
|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 30 | 24 | 25 |
| Completed | 0 | 0 | 0 | 19 | 20 | 17 |
| Not completed | 0 | 0 | 0 | 11 | 4 | 8 |
| Withdrew: Adverse event | 0 | 0 | 0 | 4 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 2 | 1 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 | 0 | 1 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 0 | 2 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 2 | 2 | 3 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 2 | 1 | 0 |
Measure of irritability symptoms of autism. Score range 0 to 45 (lower score = lesser severity).
| units on a scale | Placebo | Risperidone Low Dose | Risperidone High Dose |
|---|---|---|---|
| Change in Aberrant Behavior Checklist Irritability (ABC-I) Subscale | -3.5 ± 10.67 | -7.4 ± 8.12 | -12.4 ± 6.52 |
ABC-I is a measure of irritability symptoms of autism with score range 0 to 45 (lower score = lesser severity).
| participants | Placebo | Risperidone Low Dose | Risperidone High Dose |
|---|---|---|---|
| Number of Participants Who Had at Least 25% Improvement in ABC-I | 14 | 15 | 24 |
Investigator evaluation of severity of illness and functional impairment on a 7-point scale (1="not ill", 2="very mild", 3="mild", 4="moderate", 5="marked", 6="severe", 7="extremely severe").
| units on a scale | Placebo | Risperidone Low Dose | Risperidone High Dose |
|---|---|---|---|
| Change in Clinical Global Impression Severity (CGI-S) | -0.3 ± 0.79 | -0.4 ± 0.73 | -1.0 ± 0.78 |
Investigator impression of change over time from double-blind baseline on a 7-point scale (1="very much improved", 2="much improved", 3="minimally improved", 4="no change", 5="minimally worse", 6="much worse", 7="very much worse").
| participants | Placebo | Risperidone Low Dose | Risperidone High Dose |
|---|---|---|---|
| Number of Participants Who Had Clinical Global Impression Change Ratings of Much or Very Much Improved. | 5 | 5 | 19 |
| mg/dL | Placebo | Risperidone Low Dose | Risperidone High Dose |
|---|---|---|---|
| Change in Fasting Glucose (mg/dL) at 6 Weeks | -0.4 ± 8.20 | -0.1 ± 8.81 | -0.3 ± 9.74 |
Insulin resistance calculated using the homeostatic model assessment 1 (HOMA1)formula: fasting glucose (mmol/L) times fasting insulin (uU/L) divided by 22.5. HOMA-IR is a widely used clinical tool for estimating insulin resistance based upon the balance between glucose output and insulin secretion. Normal values should be close to 1, while an increase indicates a decrease in insulin sensitivity (or increase in insulin resistance), a potential predictor for the development of Type 2 Diabetes Mellitus.
| units on a scale | Placebo | Risperidone Low Dose | Risperidone High Dose |
|---|---|---|---|
| Change in Insulin Resistance (IR) at 6 Weeks | 0.36 (-0.34 to 1.07) | -0.10 (-0.76 to 0.55) | 0.45 (-0.18 to 1.08) |
| mg/dL | Placebo/RIS | Ris Low Dose/RIS | Ris High Dose/RIS |
|---|---|---|---|
| Change in Fasting Glucose (mg/dL) at 6 Months | 4.0 ± 12.27 | 3.5 ± 12.26 | 2.3 ± 8.70 |
Insulin resistance calculated using the homeostatic model assessment 1 (HOMA1) formula: fasting glucose (mmol/L) times fasting insulin (uU/L) divided by 22.5. HOMA-IR is a widely used clinical tool for estimating insulin resistance based upon the balance between glucose output and insulin secretion. Normal values should be close to 1, while an increase indicates a decrease in insulin sensitivity (or increase in insulin resistance), a potential predictor for the development of Type 2 Diabetes Mellitus.
| units on a scale | Placebo/RIS | Ris Low Dose/RIS | Ris High Dose/RIS |
|---|---|---|---|
| Change in Insulin Resistance (IR) at 6 Months | 0.09 ± 2.67 | 0.36 ± 0.89 | 0.75 ± 0.91 |
Collected over Double-blind period: 6 weeks. Open-label period: 6 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 1/35 (2.9%) | 20/35 (57.1%) |
| Risperidone Low Dose | — | 0/30 (0%) | 12/30 (40%) |
| Risperidone High Dose | — | 0/31 (0%) | 27/31 (87.1%) |
| Open-label Risperidone | — | 1/79 (1.3%) | 39/79 (49.4%) |
| Event | Placebo | Risperidone Low Dose | Risperidone High Dose | Open-label Risperidone |
|---|---|---|---|---|
| AggressionPsychiatric disorders | 1/35 | 0/30 | 0/31 | 0/79 |
| HydroceleCongenital, familial and genetic disorders | 0/35 | 0/30 | 0/31 | 1/79 |
| Event | Placebo | Risperidone Low Dose | Risperidone High Dose | Open-label Risperidone |
|---|---|---|---|---|
| Increased appetiteMetabolism and nutrition disorders | 2/35 | 5/30 | 11/31 | 9/79 |
| SedationNervous system disorders | 0/35 | 1/30 | 8/31 | 6/79 |
| SomnolenceNervous system disorders | 1/35 | 0/30 | 7/31 | 4/79 |
| NasopharyngitisInfections and infestations | 2/35 | 2/30 | 4/31 | 5/79 |
| Weight increasedInvestigations | 2/35 | 3/30 | 4/31 | 7/79 |
| HeadacheNervous system disorders | 4/35 | 2/30 | 2/31 | 4/79 |
| Upper respiratory tract infectionInfections and infestations | 1/35 | 1/30 | 3/31 | 6/79 |
| VomitingGastrointestinal disorders | 2/35 | 2/30 | 2/31 | 7/79 |
| Abdominal discomfortGastrointestinal disorders | 3/35 | 0/30 | 0/31 | 2/79 |
| PyrexiaGeneral disorders | 0/35 | 0/30 | 2/31 | 6/79 |
| Age, Categorical(Participants) | Placebo | Risperidone Low Dose | Risperidone High Dose | Total |
|---|---|---|---|---|
| <=18 years | 35 | 30 | 31 | 96 |
| Between 18 and 65 years | 0 | 0 | 0 | 0 |
| >=65 years | 0 | 0 | 0 | 0 |
| Age, Continuous(years) | Placebo | Risperidone Low Dose | Risperidone High Dose | Total |
|---|---|---|---|---|
| Mean | 8.6 ± 2.57 | 10.2 ± 3.42 | 9.3 ± 3.11 | 9.3 ± 3.07 |
| Sex: Female, Male(Participants) | Placebo | Risperidone Low Dose | Risperidone High Dose | Total |
|---|---|---|---|---|
| Female | 4 | 5 | 3 | 12 |
| Male | 31 | 25 | 28 | 84 |
| Region of Enrollment(participants) | Placebo | Risperidone Low Dose | Risperidone High Dose | Total |
|---|---|---|---|---|
| United States of America | 35 | 30 | 31 | 96 |
| Age Categorical(participants) | Placebo | Risperidone Low Dose | Risperidone High Dose | Total |
|---|---|---|---|---|
| <12 years | 30 | 20 | 24 | 74 |
| >=12 years | 5 | 10 | 7 | 22 |
The record gives a start of Dec 2007, a primary completion of Sep 2009 and a completion of Mar 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2010, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. →